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he 280-kD cation-independent mannose-6-phosphate
receptor (MPR) has been shown to play a role in en-
docytic uptake of granzyme B, since target cells
overexpressing MPR have an increased sensitivity to
granzyme B–mediated apoptosis. On this basis, it has been
proposed that cells lacking MPR are poor targets for cyto-
toxic lymphocytes that mediate allograft rejection or tumor
immune surveillance. In the present study, we report that
the uptake of granzyme B into target cells is independent of
MPR. We used HeLa cells overexpressing a dominant-
negative mutated (K44A) form of dynamin and mouse ﬁbro-
 
blasts overexpressing or lacking MPR to show that the
MPR/clathrin/dynamin pathway is not required for gran-
zyme B uptake. Consistent with this observation, cells
lacking the MPR/clathrin pathway remained sensitive to
T
 
granzyme B. Exposure of K44A-dynamin–overexpressing
and wild-type HeLa cells to granzyme B with sublytic perforin
resulted in similar apoptosis in the two cell populations, both
in short and long term assays. Granzyme B uptake into MPR-
overexpressing L cells was more rapid than into MPR-null
L cells, but the receptor-deﬁcient cells took up granzyme B
through ﬂuid phase micropinocytosis and remained sensitive
to it. Contrary to previous ﬁndings, we also demonstrated
that mouse tumor allografts that lack MPR expression were
rejected as rapidly as tumors that overexpress MPR. Entry
of granzyme B into target cells and its intracellular trafﬁck-
ing to induce target cell death in the presence of perforin
are therefore not critically dependent on MPR or clathrin/
dynamin-dependent endocytosis.
 
Introduction
 
Cytotoxic T lymphocytes (CTLs)* and natural killer cells
induce contact-dependent target cell death to protect higher
organisms from overwhelming viral infection and cellular trans-
formation. Extensive studies in gene-targeted mice indicate
that these cytotoxic lymphocytes (CLs) rely principally on the
exocytosis of toxins from specialized granules stored in their
cytoplasm to kill unwanted or harmful cells (Barry and
Bleackley, 2002). The two essential components of CL secre-
tory granules are perforin, a membrane-disrupting protein,
and a family of serine proteases called granzymes, which induce
apoptosis in a perforin-dependent manner (Barry and
Bleackley, 2002). Granzyme B is the most efficient proapop-
totic granzyme (Shi et al., 1992) and the only mammalian
serine protease that can mimic caspases by cleaving substrates
at acidic residues, particularly aspartic acid (Odake et al.,
1991). Congenital deficiency of granzyme B from CL results
in delayed DNA fragmentation in target cells (Heusel et al.,
1994) and marked susceptibility of the deficient mice to the
viral pathogen ectromelia (Mullbacher et al., 1999). The
precise mechanism of perforin/granzyme B collaboration is
still not completely clear. Granzyme B is known to enter
cells in the absence of perforin through receptor-mediated
endocytosis into Rab 4/5-positive early endosomes (Shi et
al., 1997; Pinkoski et al., 1998) but is innocuous to cells unless
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perforin is also present. It is now becoming clear that per-
forin’s role is to liberate granzyme B from the endosomal
compartment into the cytosol (Browne et al., 1999) where it
accesses and cleaves the key substrate Bid, a proapoptotic
member of the Bcl-2 family, to initiate apoptosis through
the mitochondrial pathway (Barry et al., 2000; Heibein et
al., 2000; Sutton et al., 2000). Other pathways that operate
independently of Bid also exist (Thomas et al., 2001), but
they appear to be less efficient.
Although 
 
125
 
I-labeled granzyme B’s binding to the target
cell surface is saturable and can be partly competed by unla-
beled granzyme (Froelich et al., 1996), the mechanisms
governing granzyme uptake have remained unclear. Re-
cently, however, it was shown that granzyme B can enter
cells after binding the 280-kD cation-independent man-
nose-6-phosphate (M6P) receptor (MPR) and that cells
overexpressing MPR are more sensitive than parental cells
to granzyme B–mediated death (Motyka et al., 2000).
Granzymes have been known to bind to intracellular MPR
for some time in the context of the trafficking of nascent
granzyme polypeptide from the Golgi to secretory (lyso-
some-like) vesicles of CL (Griffiths and Isaaz, 1993). The
MPR is also known to traffic to the plasma membrane in
many (although not all) cells. MPR’s demonstrated ability
to internalize granzyme B is significant because in the ab-
sence of an alternative means of entering target cells MPR
would become a legitimate target to block CL-mediated cell
death by pharmacological means, for example, to block
CTL–induced tissue damage in certain autoimmune dis-
eases. It has also been proposed that cancer cells down-reg-
ulating MPR expression from their plasma membrane
might escape immune surveillance by CL, a potentially
novel tumor escape mechanism (Motyka et al., 2000). The
same mechanism might also account for the observation
that MPR can act as tumor suppressor in certain cancers,
such as human hepatocellular (De Souza et al., 1995),
breast (Chappell et al., 1997), and renal (Morita et al.,
1991) carcinomas. A further important claim in respect to
MPR was that its expression is required for rejection of an
allogenic tumor graft across a complete H-2 haplotype mis-
match (Motyka et al., 2000). Clearly, such a finding, if cor-
roborated, would be profoundly important for clinical or-
gan transplantation.
Although it is clear that MPR is one mechanism through
which granzyme B can enter the target cell, no study has yet
determined the susceptibility of cells to granzyme B/perforin-
induced cell death in the absence of a functional MPR path-
way. Given the importance of granzyme-mediated death
pathways in infectious and neoplastic diseases (Trapani and
Smyth, 2002), we set out to examine whether the MPR path-
way is critical for granzyme B–mediated cell death. In the
present study, we show that the absence of the clathrin-
dependent MPR endocytic pathway reduces but does not
abolish granzyme B uptake and, importantly, has little effect
on cell death. Furthermore, we found that MPR expression
was not required for rejection of an alloreactive tumor from
the subcapsular space of the kidney in immunocompetent
BALB/c and C57BL/6 mice. Therefore, other constitutive
mechanisms exist in most cells for uptake of granzymes that
are independent of MPR-dependent endocytosis.
 
Results
 
It has been demonstrated recently that overexpression of
MPR in mouse L cells makes them more sensitive to
granzyme B–induced apoptosis (Motyka et al., 2000). How-
ever, no study has examined whether the absence of MPR
compromises apoptosis in response to granzyme B, either in
vitro or in vivo. High concentrations of the competitor
monosaccharide M6P in the previous study failed to com-
pletely abrogate cell death through granzyme B, leaving
open the possibility that alternative pathways exist for
granzyme B uptake into target cells (Motyka et al., 2000).
Therefore, we wished to determine whether cells in which
granzyme B cannot be taken up through the MPR remain
susceptible to granzyme B–mediated cell death.
 
Granzyme B uptake is slowed but not abolished in 
K44A mutant–dynamin–expressing HeLa cells
 
To address the above issues, we performed studies in two
sets of stably transfected cell lines, human HeLa cells and the
same mouse L cell fibroblasts (C3H and H-2
 
k
 
) used in the
previous report (Motyka et al., 2000). Molecules that bind
to cell surface MPR (and most other cell surface receptors
including the transferrin receptor) are endocytosed via clath-
rin-coated pits and vesicles (Pearse and Robinson, 1990). In
the first set of experiments addressing the question of
granzyme B uptake, we used a previously well-characterized
transfectant HeLa cell line expressing a mutated dynamin
(K44A) that is a dominant-negative inhibitor of clathrin-
dependent endocytosis (Damke et al., 1994). Dynamin’s nor-
mal function is to permit the separation of clathrin-coated
pits from the plasma membrane into the cytoplasm, thus en-
abling the trafficking of vesicles and their extracellular cargo
to the late endosomal compartment, and ultimately to lyso-
somes (Damke et al., 1994). Expression of K44A-dynamin
in the HeLa cell populations is regulated by a tetracycline
(tet)-sensitive promoter so that growth in tet-deficient me-
dium resulted in overexpression of K44A-dynamin. As a
control, wild-type dynamin was overexpressed in HeLa cells
using the same promoter.
Expression of K44A-dynamin has been shown to result in
retention of some ligands, including transferrin at the
plasma membrane, whereas other ligands fail to accumulate
on the cell surface (Damke et al., 1994). To demonstrate the
induction of K44A-dynamin expression, cells grown in the
presence of tet or in the absence of tet for 48 h were incu-
bated at 37
 
 
 
C with FITC-labeled transferrin (FITC-trans-
ferrin) and then viewed by confocal laser scanning micros-
copy. As expected, HeLa cells in which K44A-dynamin
expression was repressed by tet demonstrated strong uptake
of FITC-transferrin into cytoplasmic vesicles. In addition,
most of the cells demonstrated punctate fluorescence at the
plasma membrane, indicating multifocal binding to the
transferrin receptor (Fig. 1a). In cells grown in tet-deficient
medium, the fluorescence was largely restricted to the
plasma membrane and few vesicles were internalized, consis-
tent with defective clathrin-dependent uptake of FITC-
transferrin. Fewer than 10% of cells demonstrated clear
vesicular uptake under these conditions after 120 min, al-
though some residual fluorescence was seen in the cyto-T
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plasm, consistent with constitutive uptake through fluid
phase micropinocytosis, which is known to remain active in
these cells (see below). Despite the demonstrated potent in-
hibition of receptor-dependent endocytosis in these cells
(Damke et al., 1994), 
 
 
 
90% of K44A-dynamin–expressing
cells incubated with FITC–granzyme B showed cytoplasmic
fluorescence, which increased with time (Fig. 1 b, 
 
 
 
tet) and
was far above levels of autofluorescence (see below). No cell
surface binding of FITC–granzyme B was seen at either 4
 
 
 
C
(unpublished data) or 37
 
 
 
C, and the cytoplasmic staining
pattern was less obviously punctate than seen when only
wild-type dynamin was expressed. These findings were again
consistent with fluid phase uptake of granzyme B. Control
cells expressing only wild-type dynamin showed consistent
cell surface and punctate vesicular staining with FITC–
granzyme B similar to that seen with FITC-transferrin (Fig.
1 b, 
 
 
 
tet) and reminiscent of granzyme B trafficking ob-
served previously in Jurkat or FDC-P1 cells (Jans et al.,
1996; Browne et al., 1999; Motyka et al., 2000). Similar
HeLa cell transfectants that overexpressed wild-type dy-
namin upon withdrawal of tet showed normal vesicular up-
take of both FITC–granzyme B and FITC-transferrin
(Damke et al., 1994; data not shown).
The significant cytoplasmic fluorescence of K44A-
dynamin–expressing cells exposed to granzyme B was con-
firmed and quantitated by laser scanning microscopy and
image analysis (Fig. 1 c). As measured by the ratio of cyto-
plasmic to extracellular fluorescence (Fc/Fmed), cells overex-
pressing K44A-dynamin had taken up quantities of FITC–
granzyme B equivalent to cells expressing only wild-type
dynamin at the earliest time point that could practically be
studied (t 
 
  
 
5 min). Over the next 2 h, the K44A-dynamin–
overexpressing cells took up less granzyme B than control
cells. A control unglycosylated fluorescent protein (GFP)
that cannot bind to MPR was taken up equally well into
K44A- or wild-type dynamin-expressing cells by fluid phase
micropinocytosis. Overall, these results suggested rapid but
low level constitutive fluid phase uptake of granzyme B (and
GFP) together with more prolonged uptake of granzyme B
through receptor-dependent endocytosis. Our results for
granzyme B uptake were not explained by the uptake of free
FITC or degraded FITC–granzyme B, since the cytoplasmic
fluorescence was inhibited in a dose-dependent manner by
coadding unlabeled granzyme B (see below). Using a poly-
clonal anti-MPR antiserum, we also showed that the HeLa
cells expressed equivalent levels of MPR at the cell surface,
irrespective of whether mutated or wild-type dynamin was
expressed (unpublished data).
As described above, we postulated that the residual
granzyme B uptake in K44A-dynamin–expressing cells was
due to an alternative, clathrin/dynamin-independent uptake
pathway. However, it was also plausible that the level of
K44A-dynamin expression in the HeLa transfectants was in-
sufficient to completely block granzyme B uptake through
the clathrin-dependent MPR pathway. To distinguish be-
tween these possibilities, we incubated the K44A-dynamin–
expressing cells with FITC–granzyme B in the presence of 5
mM mannose-6-phosphate, which represents a 100,000-
fold molar excess of the monosaccharide over granzyme B
(typically used at 25–75 nM). As a control, we added a simi-
lar concentration of glucose-6-phosphate (G6P), which is
unable to bind to MPR (Motyka et al., 2000). As expected,
uptake of FITC–granzyme B into HeLa cells expressing only
wild-type dynamin was considerably reduced by M6P,
whereas G6P had no effect (Fig. 2). By contrast, preincuba-
tion of cells with M6P did not diminish granzyme B uptake
in K44A-dynamin–expressing HeLa cells, indicating that
uptake of granzyme B through the MPR/clathrin pathway
was already efficiently blocked in these cells. Overall, our re-
sults strongly suggested that granzyme B is able to enter the
cell cytoplasm using a mechanism that is independent of the
MPR/clathrin pathway.
Figure 1. Residual uptake of granzyme B by K44A mutant dynamin–
overexpressing HeLa cells. (a) Confocal micrograph of HeLa cells 
overexpressing K44A mutant dynamin ( tet) or in which expression 
of mutant dynamin is suppressed ( tet) after exposure to FITC-
transferrin for 120 min. (b) Confocal micrograph of K44A HeLa cells 
after exposure to FITC–granzyme B (50 nM) for 60 or 120 min. 
(c) Uptake of FITC–granzyme B (grB) or unglycosylated GFP by HeLa 
cells overexpressing wild-type (WT) or K44A-mutated dynamin for 
the times indicated. Uptake of either fluoresceinated molecule into 
the cell cytoplasm was quantitated by confocal laser scanning 
microscopy and image analysis as described (Jans, 1995; Jans et al., 
1996). The results are expressed as a ratio between cytoplasmic 
fluorescence (Fc) and extracellular fluorescence (Fmed)   standard 
error of the mean. Each data point was derived from measurements 
on at least 30 cells selected at random after substruction of 
autofluorescence (as described in Materials and methods).T
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K44A-dynamin–overexpressing HeLa cells are not 
protected from granzyme B–induced cell death
 
We next determined whether K44A-overexpressing cells are
protected from cell death mediated by granzyme B. We ini-
tially measured specific 
 
51
 
Cr release in response to granzyme B
delivered either by sublytic quantities of perforin or an alter-
native lytic agent, pneumococcal pneumolysin (PLO), which
has been shown to closely mimic perforin’s delivery of
granzyme B (Browne et al., 1999). In this context, 
 
51
 
Cr re-
lease is a measure of plasma membrane permeability during
apoptosis and is a reliable short term measure of cell survival
in response to granzyme B (Sutton et al., 1997; Trapani et al.,
1998). Addition of granzyme B (50 nM) with either perforin
or PLO induced equivalent 
 
51
 
Cr release from K44A- and
wild-type dynamin-overexpressing cells over 4 h (Fig. 3 a).
This result is reminiscent of an experiment of Motyka et al.
(2000) who showed that MPR-overexpressing and MPR-null
L cells released equivalent 
 
51
 
Cr when they were attacked by
intact CTL. The authors attributed the surprisingly high 
 
51
 
Cr
release in cells lacking the MPR/clathrin pathway to perforin-
mediated lysis and ruled out the effect as being caused by
granzyme B. However, our experiment performed with the
same cell lines and purified perforin and granzyme B clearly
showed that, even in the absence of MPR, granzyme B is able
to synergize with perforin or PLO to induce 
 
51
 
Cr release. In
this setting, the release of 
 
51
 
Cr therefore reflects the loss
of plasma membrane integrity as the result of granzyme
B–induced apoptosis, not necrosis (lysis), in response to per-
forin. We also confirmed that K44A- and wild-type dynamin-
expressing cells were equally susceptible to granzyme B/per-
forin in assays of clonogenic survival. There was an equivalent
dose-related reduction in colony numbers as the concentra-
tion of granzyme B increased, irrespective of whether the
MPR/dynamin pathway was functional or not (Fig. 3 b).
 
Granzyme B uptake and cell death in MPR-null L cells
 
Our second series of experiments used mouse L cell fibro-
blasts either null for MPR expression or overexpressing hu-
man MPR as had been studied previously (Nolan et al.,
1990; Motyka et al., 2000). The L cells overexpressing MPR
(designated MS9-II) became strongly fluorescent after incu-
bation for 10 min at 37
 
 
 
C with FITC–granzyme B and
showed a similar pattern of fluorescence when viewed by
confocal microscopy as described above for HeLa cells (Fig.
4 a). The staining pattern in most cells also clearly showed a
predominant concentrated area of cytoplasmic fluorescence
consistent with transport of ligand to the late endosomal
compartment. The MPR-null MS cells (which had been
transfected with vector DNA alone) were less strongly fluo-
rescent at the same time point but still showed significant
uptake of FITC–granzyme B compared with autofluores-
cence controls (Fig. 4 a). As was seen with the K44A-overex-
pressing HeLa cells, MS cells also showed minimal cell sur-
face binding of FITC–granzyme B, whereas strong plasma
membrane binding was seen in MS9-II cells. It was evident
from kinetic studies in which FITC–granzyme B uptake was
quantitated on a cytofluorograph that granzyme B uptake in
MS cells could be partially compensated by longer incuba-
Figure 2. Granzyme B uptake into K44A mutant 
dynamin–overexpressing HeLa cells is not inhibited 
by a vast molar excess of M6P. Cytofluorographic 
analysis of HeLa cells overexpressing K44A mutant 
dynamin ( tet, bottom) or expressing only wild-type 
dynamin ( tet, top) after incubation with FITC–
granzyme B (50 nM) at 37 C for 20 min or in the 
absence of FITC–granzyme B (filled traces). Cells were 
preincubated either with 5 mM M6P (red) or G6P 
(blue) or without competing monosaccharide (green) 
for 15 min at 37 C.T
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tion. Whereas FITC–granzyme B uptake into MS9-II cells
had reached maximal steady-state levels within 10 min, the
fluorescence of MS cells had increased somewhat but still re-
mained below that of MS9-II cells after 40 min (Fig. 4 b).
To characterize the residual uptake of granzyme B into
MPR-null MS cells, we next performed a quantitative, ki-
netic analysis of granzyme B uptake using quantitative laser-
scanning microscopy of several hundred cells. Cells were
preincubated with FITC–granzyme B at 4
 
 
 
C to allow sur-
face binding and then rapidly transferred to 37
 
 
 
C to per-
mit uptake into the cytoplasm. Consistent with the overex-
pression of MPR on the surface of MS9-II cells, FITC–
granzyme B binding at the plasma membrane (expressed as
the ratio of fluorescence at the plasma membrane to that in
Figure 3. K44A-dynamin–overexpressing HeLa cells are not 
protected from granzyme B–induced cell death. (a) 
51Cr-labeled 
HeLa cells overexpressing either K44A- or wild-type (WT) dynamin 
were incubated with sublytic perforin (Pfp) or pneumolysin (PLO) 
either alone or together with granzyme B (50 nM) for 90 min at 
37 C. Specific 
51Cr release is shown as the mean of triplicate data 
points   standard error. The assay is representative of three similar 
experiments. (b) Clonogenic survival of K44A- or wild-type (WT) 
dynamin-overexpressing HeLa cells after incubation with sublytic 
perforin (Pfp) and various concentrations of granzyme B. Results are 
shown as the percentage inhibition of colony growth (mean of three 
cultures   standard error at each granzyme concentration) compared 
with untreated cells. Typically, 75–150 HeLa colonies became 
evident when the cells were untreated. The experiment shown 
is representative of four similar experiments (as described in 
Materials and methods).
Figure 4. Residual uptake of granzyme B by MPR-null L cell 
fibroblasts. (a) Confocal micrograph of MS (MPR-null) and MS9-II 
(MPR-overexpressing) L cells after exposure to FITC–granzyme B 
(50 nM) for 60 min at 37 C or without addition of FITC–granzyme B 
(autofluorescence [AF], bottom). Association of granzyme B with 
the plasma membrane (m) and in the late endosomal compartment 
(l) are shown. (b) Cytofluorographic analysis of MS and MS9-II cells 
after incubation with FITC–granzyme B (50 nM) at 37 C for the 
times indicated or in the absence of FITC–granzyme B (filled traces).T
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the extracellular medium, Fpm/Fmed) had reached maximal
levels within 5 min and gradually diminished as the cells
took up granzyme B into their cytoplasm (Fig. 5 a). Consis-
tent with uptake through a cell surface receptor (MPR), pre-
incubation with a 10-fold excess of unlabeled granzyme B
virtually abolished plasma membrane fluorescence (Fig. 5 a,
t 
 
 
 
 5 min and later time points). By comparison, the level of
plasma membrane staining of MS cells was much lower, did
not vary over time, and was unaffected by the addition of
unlabeled competitor. The finding that unlabeled granzyme
 
B could block cell surface fluorescence of MS9-II but not
MS cells indicated that although uptake of granzyme B into
MS9-II cells was largely dependent on binding to MPR, the
uptake into MS cells was not mediated by a cell surface re-
ceptor. Despite this, and consistent with findings presented
above (Fig. 4), the cytoplasmic accumulation of FITC–
granzyme B (Fc/Fmed) was not abolished in MS cells, al-
though it was, as expected, reduced in comparison with
MS9-II cells (Fig. 5 b). Significant and equivalent fluid
phase uptake of unglycosylated GFP was seen into both cell
lines, which did not vary appreciably over the 2 h of study.
The trafficking of FITC–granzyme B to the late endosomal
compartment (measured as the ratio of fluorescence of the
late endosomal compartment and extracellular fluorescence,
Flc/Fmed) was also much more rapid in MS9-II cells than
MS cells and was markedly slowed by preaddition of unla-
beled competitor, whereas trafficking to this compartment
in MS cells was far less prominent and not influenced by
competitor (Fig. 5 c).
Characterization of the kinetics of FITC–granzyme B en-
try into specific subcellular compartments of MS cells (Fig.
5, a–c) strongly suggested uptake through fluid phase en-
docytosis. First, MS cells showed no evidence of granzyme B
binding to receptors on the plasma membrane that could be
competed by unlabeled granzyme, whether at 4 or 37
 
 
 
C.
Second, despite this, cytoplasmic accumulation of granzyme
B was still observed in MS cells. Third, although the accu-
mulation of FITC–granzyme B in the cytoplasm and the
late endosomal compartment was significantly inhibited by
unlabeled granzyme B in MS9-II cells, this was not the case
in MS cells.
Our next aim was to compare the susceptibility of MS and
MS9-II cells to granzyme B–mediated death. To try to max-
imize any difference between the two cell lines, they were ex-
posed to limiting concentrations of granzyme B (3 and 12
nM) together with sublytic PLO for 1 h before quantitating
cell death in clonogenic assays (Fig. 6 a). At these limiting
granzyme B concentrations, the MPR-overexpressing cells
were about twofold more susceptible to cell death, but the
MPR-null MS cells were also sensitive, and there was no dif-
ference in colony formation when a slightly higher but con-
ventional granzyme B concentration (50 nM) or higher
concentrations (unpublished data) were used. To put the
granzyme B concentrations we used in context, concentra-
tions in the 1–5-
 
 
 
M range have been used by other investi-
gators in similar assays (Thomas et al., 2000, 2001). The re-
lease of 
 
51
 
Cr from MS cells after exposure to granzyme B and
lytic agent was also reduced compared with MS9-II cells,
but the difference between the two cell lines diminished
with time (Fig. 6 b). After 1 h, the release of 
 
51
 
Cr by MS
cells was only 35% that of MS9-II cells, but by 6 h the re-
lease by MS cells had reached 60% of MS9-II.
The susceptibility of MPR-overexpressing and MPR-null
L cells was also examined in response to intact allogenic
CTL. Effector cells raised in both BALB/c (d anti-k) or
C57BL/6 (b anti-k) mice induced the equivalent release of
 
51
 
Cr release from MS and MS9-II cells over a 4-h assay.
However, MPR-null MS cells demonstrated significantly re-
duced DNA fragmentation (Fig. 7). DNA damage in both
populations of L cells was virtually totally dependent on
Figure 5. Quantitative kinetic analysis of the uptake of FITC–
granzyme B into MS and MS9-II cells. Uptake of FITC–granzyme B 
(grB) or unglycosylated GFP by MS (MPR-null) and MS9-II (MPR-
overexpressing) L cells. The uptake of both fluoresceinated molecules 
onto the plasma membrane (top) into the cell cytoplasm (middle) or 
into the late endosomal compartment (bottom) was quantitated by 
confocal laser scanning microscopy and image analysis as described 
previously (Jans, 1995). The results are expressed as a ratio between 
total cytoplasmic fluorescence (Fc), plasma membrane fluorescence 
(Fpm), or fluorescence of the late endosomal compartment (Flc) and 
extracellular fluorescence (Fmed)   standard error of the mean. 
Each data point was derived from measurements on at least 30 cells 
selected at random after subtraction of autofluorescence (as described 
in Materials and methods).T
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granzyme B, since granzyme B–deficient C57BL/6 CTL
were unable to induce any release of 
 
125
 
I-DNA from either
cell line. Overall, our results were consistent with a role for
the granzyme B-MPR pathway in facilitating DNA frag-
mentation rather than significantly influencing cell survival.
 
MPR is not required for allograft rejection
 
The previous report by Motyka et al. (2000) indicated that
MS cells (H-2
 
k
 
) implanted beneath the kidney capsule of
BALB/c mice (H-2
 
d
 
) were not rejected and grew to form tu-
mors, whereas MPR-overexpressing MS9-II cells were rap-
idly rejected. This finding suggested a pivotal role for MPR
in allotransplantation, with possible significant implications
for the therapy of allograft rejection. Because of their poten-
tial importance, we decided to perform similar experiments
with some additional controls. Consistent with the previous
study, both MS and MS9-II cells formed rapidly growing
tumors when implanted beneath the kidney capsule of im-
mune-compromised BALB/c.
 
scid/scid
 
 mice. MS9-II tumors
grew somewhat more rapidly and invaded the kidney paren-
chyma more readily than MS (Fig. 8, a and b). By contrast,
both cell lines failed to form tumors in immunocompetent
BALB/c mice. 7 d after implantation, small areas of MS9-II
tumor could be identified histologically, invariably infil-
trated with mononuclear cells, whereas MS tumor could not
be identified (Fig. 8, c and d). By 14 d, both tumors were
completely eradicated (Fig. 8, e and f). To determine the
role of the granule (i.e., perforin/granzyme) pathway in this
tumor rejection model, syngeneic perforin-deficient animals
were inoculated with the same tumors. Surprisingly, both
tumors were again rejected. Once more, transient tumor
growth was seen in some animals at 7 d; however, complete
rejection of both tumors occurred by day 14 (Fig. 8, g–j),
leaving only dilated blood vessels, capsular thickening, and a
patchy mononuclear cell infiltrate (Fig. 8 k). To assess tu-
mor rejection in a different strain combination, we repeated
the experiment in C57BL/6 (H-2
 
b
 
) and granzyme B–defi-
cient animals on the C57BL/6 background. Once again,
both tumors were rejected (unpublished data). Collectively,
Figure 6. MPR-null L cells are not protected from granzyme
B–induced cell death. (a) Clonogenic survival of MS and MS9-II 
cells after incubation with sublytic pneumolysin (PLO) alone or with 
various concentrations of granzyme B at 37 C for 90 min. Results 
are shown as the percentage inhibition of colony growth (mean of 
three cultures   standard error at each granzyme concentration) 
compared with untreated cells. Typically, 75–150 L cell colonies 
grew when the cells were untreated. The experiment shown is 
representative of four similar experiments (as described in Materials 
and methods). (b) 
51Cr-labeled MS or MS9-II cells were incubated 
with sublytic pneumolysin (PLO) alone or together with granzyme B 
(50 nM) at 37 C for the times indicated. Specific 
51Cr release is 
shown as the mean of triplicate data points   standard error. The 
assay is representative of three similar experiments.
Figure 7. Reduced DNA fragmentation but not membrane 
permeability in MPR-deficient L cells killed by alloreactive CTL. 
MS and MS9-II cells (H-2k) were prelabeled simultaneously with 
51Cr and 
125I-deoxyuridine, then incubated at 37 C for 4 h at the 
effector-to-target cell ratios indicated with alloreactive CTL raised in 
BALB/c (H-2d), C57BL/6, or C57BL/6.grB
 /  (H-2b) mice (as described 
in Materials and methods). Specific release of 
51Cr (indicating cell 
membrane permeability) and 
125I-DNA (DNA fragmentation) were 
estimated as the mean of triplicate data points  standard error. The 
experiment shown is representative of four similar experiments.T
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our findings clearly indicated that (a) MPR is not required
for allograft rejection across a major histocompatibility mis-
match and (b) rejection of both MS and MS9-II cells occurs
independently of the granule pathway. In other experiments
(unpublished data), we also found that Fas ligand mutant
(gld) mice rejected MS and MS9-II tumors, indicating that
cell death was not achieved through the Fas pathway.
Since rejection of both MS and MS9-II tumors by immu-
nocompetent mice did not require either the perforin/
granzyme or Fas pathways, we hypothesized that rejection in
this model might be antibody mediated. Consistent with this
hypothesis, when MS9-II cells were used to inoculate synge-
neic C3H mice, the tumors also failed to grow and the mice
developed high titer antibodies that reacted with MS9-II cells
Figure 8. Growth of MS and MS9-II L 
cell tumors in immune-deficient BALB/
c.scid/scid mice, but rejection by 
immunocompetent mice and mice 
lacking perforin expression. MS or MS9-II 
cells were inoculated under the kidney 
capsule of groups of four recipients of 
the mouse strains indicated (as described 
in Materials and methods). Either 7 or 14 d 
later, the mice were killed and histological 
analysis of the kidneys was performed 
using hematoxalin and eosin staining 
of the formaldehyde-fixed tissues. 
Magnifications: (a–j) 200 ; (k) 400 . 
BV, blood vessel; CT, connective tissue; 
L, mononuclear infiltrate.T
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and at lower but significant levels with MS cells. Typically,
the antibody titers by indirect immunofluorescence were 
 
 
 
1/
1,600 on MS9-II cells and 1/200 on MS cells (unpublished
data). We concluded that human MPR expressed on MS9-II
cells is a target of the anti–MS9-II antibody response. As a re-
sult of long term culture in vitro, it is also likely that MS and
MS9-II express other immunogenic antigens responsible for
perforin/granzyme B–independent rejection of MS cells. To
definitively demonstrate a role for antibody in tumor rejec-
tion in vivo, we adoptively transferred serum from C3H mice
that had been challenged twice with MS9-II cells into four
BALB/c.
 
scid.scid
 
 mice 1 d before, and on the same day as
they were implanted with MS9-II cells under the kidney cap-
sule. Control mice received serum from unimmunized C3H
mice. 7 d later, tumor growth was clearly evident in four out
of four control mice; however, three out of four mice pre-
treated with anti–MS9-II antiserum showed complete ab-
sence of tumor, whereas the fourth mouse showed signifi-
cantly reduced tumor mass (representative data in Fig. 9).
These results clearly indicated that rejection of MS9-II was
antibody mediated in immunocompetent animals and re-
lated to expression of immunogenic (human) MPR by these
cells. Therefore, MPR played no role in cell-mediated tumor
allograft rejection in these or the previously reported studies.
 
Discussion
 
It is known that granzyme B is able to bind to MPR, both in
the context of intracellular trafficking in a CL in which it is
synthesized (Griffiths and Isaaz, 1993) and when MPR is ex-
pressed on the surface of a target cell (Motyka et al., 2000).
Since overexpression of MPR on the cell surface enables a
cell to take up greater quantities of granzyme B through en-
docytosis, it is not surprising that such a cell should be a bet-
ter target for the granzyme B death pathway in concert with
perforin (Motyka et al., 2000; this study). However, no
study has previously determined whether susceptibility to
granzyme B–induced death is lost if MPR is absent or up-
take through it is abolished. The significance of the present
study is that it sought to determine whether cells in which
granzyme B cannot be taken up through the MPR remain
susceptible to granzyme B–mediated cell death either in
vitro or in vivo. Our findings clearly indicate that human
HeLa cells and mouse L cells possess more than one pathway
for taking up granzyme B into their cytoplasm. One path-
way utilizes granzyme B binding to MPR as described previ-
ously. However, MPR binding is not critical to granzyme
B–induced cell death, since constitutive nonreceptor-medi-
ated fluid phase endocytosis effectively delivers proapoptotic
granzyme B independently of MPR. Consistent with “bulk”
Figure 8 continued
Figure 9. Adoptive transfer of 
anti–MS9-II antiserum mediates graft 
rejection. MS9-II cells were inoculated 
under the kidney capsule of groups of 
four BALB/c.scid.scid recipients (as 
described in Materials and methods). 
The groups received nonimmune C3H 
serum (a) or anti–MS9-II antiserum as 
described in Materials and methods. 
Magnification, 200 .T
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uptake of granzyme B, this second pathway is characterized
by a lack of appreciable granzyme B binding to the plasma
membrane and lack of inhibition of cytoplasmic uptake by
unlabeled competitor granzyme. It is known that fluid phase
endocytosis remains active in K44A-dynamin–expressing
cells, and indeed, HeLa cells can survive near total blockade
of the clathrin/dynamin pathway through the constitutively
active fluid phase mechanism, enabling the uptake of essen-
tial nutrients (Damke et al., 1995).
Although virtually all receptor-mediated uptake is thought
to be blocked in K44A-dynamin–expressing cells, the defect
in uptake in MS cells is restricted to MPR. This difference
between our two models is significant for two reasons. First,
since ligand/receptor complexes other than MPR and its
cargo can be taken up normally into MS cells, the fluid
phase uptake of granzyme B cannot be considered an aberra-
tion seen only when the clathrin/dynamin-mediated uptake
is completely nonfunctional. This means that both receptor-
mediated and receptor-independent uptake of granzyme B
can coexist in the same cell. Second, the fact that fluid phase
uptake was observed in MPR-deficient MS cells suggests
that no other cell surface receptor capable of binding
granzyme B with physiologically relevant avidity is expressed
by these cells. We cannot totally exclude the possibility that
cell surface receptors other than MPR exist for granzyme B;
however, their absence from L cells indicates that, unlike
MPR, they are not expressed in every cell type.
Perturbation of MPR expression has been causally associ-
ated with certain malignancies, particular with hepatocellu-
lar dysplasia and carcinoma. Loss of heterozygosity at the
MPR locus is relatively common in these tumors as are mu-
tations in the remaining allele. Thus, MPR can function as a
tumor suppressor gene in some tissues (Morita et al., 1991;
De Souza et al., 1995; Chappell et al., 1997). Given the re-
cent finding that MPR can bind granzyme B (Motyka et al.,
2000; this study), it is tempting to interpret the loss of MPR
function as a means of tumor escape from CL attack, partic-
ularly as CL are important in defense against hepatitis vi-
ruses that frequently predispose to malignant transforma-
tion. Such speculation must as yet be tempered by the
observation that MPR plays many important functions
other than binding granzyme B. MPR binds to several
ligands that can affect cell proliferation and differentiation,
including insulin-like growth factor II (Oka and Czech,
1986), the precursor form of transforming growth factor 
 
 
 
(Kovacina et al., 1989), and leukemia inhibitory factor
(Blanchard et al., 1998), that might equally influence malig-
nant transformation through alternative mechanisms.
 
Materials and methods
 
Mice
 
BALB/c, BALB/c.
 
scid/scid
 
, BALB/c.Pfp
 
 
 
/
 
 
 
 (perforin-deficient), C57BL/6,
C57BL/6.gzmB
 
 
 
/
 
 
 
 (granzyme B-deficient), and C3H mice were purchased
from the Walter and Eliza Hall Animal Facility (Parkville, Australia) or bred
at the Peter MacCallum Cancer Institute Animal Facility. The Peter Mac-
Callum Cancer Institute Animal Welfare Committee approved the animal
studies described herein.
 
Chemicals and reagents
 
Human perforin was purified from the natural killer cell line, YT, as de-
scribed (Sutton et al., 1997). PLO was obtained from Dr. James Paton
 
(Women’s and Children’s Hospital, Adelaide, South Australia) and acti-
vated in PBS-containing 
 
 
 
-mercapto-ethanol. A sublytic dose of perforin or
PLO was defined as producing 
 
 10% specific release of 
51Cr in a 4-h as-
say at 37 C and was determined independently for each cell line. Native
human granzyme B was immunopurified from YT cell lysates as described
(Trapani et al., 1993). The granzyme B was free of other granzyme activi-
ties and perforin as demonstrated by Western blotting and proteolytic as-
says, respectively. Purified granzyme B and human transferrin (purchased
from Sigma-Aldrich) were labeled with FITC as described (Trapani et al.,
1996) and stored at 4 C until use. Polyclonal antiserum detecting MPR was
a gift from Dr. William Sly (Washington University, St. Louis, MO). The
monosodium salts of G6P and M6P were purchased from Sigma-Aldrich,
dissolved in PBS at 200 mM, and stored at –20 C.
Cell lines
HeLa cells stably overexpressing either mutated (K44A) or wild-type dy-
namin under the control of a tet-sensitive promoter were obtained from Dr.
Sandra L. Schmid (The Scripps Research Institute, La Jolla, CA). The cells
were maintained in DME medium containing 10% FBS, G418 (400  g/ml),
puromycin (200  g/ml), L-glutamine (2 mM), and tet (1  g/ml). To induce
expression of dynamin, the cells were harvested, washed, and resuspended
in medium lacking tet for 24 h at 37 C. The cells were then grown in fresh
tet-free medium for a further 24 h before use. The mouse L cell line MS9-II
(H-2
k) derived by overexpressing the human MPR in MPR-null L cells was
obtained by permission of Dr. William Sly (Washington University, St. Louis,
MO), from Dr. Chris Bleackley (University of Alberta, Alberta, Canada) (Mo-
tyka et al., 2000). Parental MPR-deficient MS cells transfected with vector
DNA alone were used as a control in all experiments (Motyka et al., 2000).
Cell death assays
Allogenic (anti-H-2
k) CTL were raised by immunizing BALB/c (d anti-k) or
C57BL/6 (b anti-k) mice with freshly isolated C3H splenocytes (5   10
5)
injected into each hind footpad in PBS (50  L). The immunization was re-
peated 2 wk later. 4 d after the second immunization, the mice were killed
and the popliteal lymph nodes were isolated, teased into a single cell sus-
pension, plated at 5   10
6 cells/ml in RPMI medium, and cultured at 37 C
for 3 d in a humidified CO2 incubator. The cells were then harvested and
used in cytotoxicity assays. The specific release of 
51Cr, a measure of
plasma membrane permeability, and 
125I-DNA from target cells, a measure
of DNA fragmentation, were determined as described (Sutton et al., 1997).
For clonogenic survival assays, HeLa cell transfectants were plated in trip-
licate at  150 cells/well in the presence or absence of tet into a 24-well
plate. Cells were incubated with perforin (or PLO in some experiments) in
the presence or absence of granzyme B (3–50 nM) for 2 h at 37 C. The
wells were then flooded with medium containing 10% (vol/vol) FBS and
incubated for a further 3–5 d at 37 C when discrete colonies were
counted. Similar colony-forming assays were also performed with MS and
MS9-II cells.
Confocal microscopy and FACS
® analysis
HeLa cells grown in the presence or absence of tet were washed in Hank’s
buffered salt solution (HBSS), incubated with FITC–granzyme B or FITC-
transferrin for 10–45 min at 37 C, then washed, fixed in 2% PFA, and cen-
trifuged onto glass slides before confocal microscopy. In some experi-
ments, cells were preincubated in HBSS containing M6P or G6P (5 mM)
for 15 min before adding FITC–granzyme B or FITC-transferrin and analy-
sis by flow cytometry. For quantitative and kinetic studies of granzyme B
uptake, cells were exposed to FITC–granzyme B for various times at 37 C,
and uptake onto the plasma membrane or into the cell cytoplasm was
evaluated as described previously (Jans, 1995). Image analysis on digitized
confocal images was performed using the Macintosh NIH Image 1.49 pub-
lic domain software.
Transplantation experiments
Sterile MS or MS9-II L cell fibroblasts (certified Mycoplasma free) were har-
vested in logarithmic growth phase, washed several times in PBS, and re-
suspended at 100 million cells/ml in PBS. Mice (groups of four of each
strain) were deeply anaesthetised with methoxyflurane, placed in the su-
pine position under a heat lamp, and a midline incision was made through
the skin, fascia, and peritoneum. Each kidney, in turn, was identified and a
small incision was made in the kidney capsule, close to its caudal pole.
Under a dissecting microscope, a flexible plastic cannula was introduced
through the incision into the subcapsular space and advanced carefully to-
ward its cephalad pole. Cells (2 million in 20  L PBS) were then deposited
into the subcapsular space, and the cannula slowly withdrawn. The skin
and peritoneum were repaired, and the animals were allowed to recoverT
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from anesthesia under the heat lamp for  1 h. After 7 or 14 d, the animals
were killed by cervical dislocation, and the kidneys were recovered and
fixed immediately in formaldehyde for sectioning, hematoxalin/eosin
staining, and histological analysis. In some experiments, mice were bled
after various time intervals to quantify antibody responses to the tumors.
In another experiment, eight C3H mice were injected subcutaneously
with 5 million live MS-9 cells (without adjuvant) on two occasions, 14 d
apart. 10 d later, the mice were killed, and their total blood volume was im-
mediately harvested by cardiac puncture under direct vision. Serum was
prepared from the pooled blood and from the same number of unimmu-
nized C3H mice and stored at –80 C until required. Groups of 4 BALB/c.scid
mice were inoculated with 1.0 ml of serum from either the immunized or
unimmunized mice into the peritoneal cavity 1 d before and on the same
day as they were injected with MS-9 cells under the kidney capsule, exactly
as described above. The mice were killed 7 d later, and their kidneys were
recovered, fixed, and examined histologically as described above.
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